Selective Targeting of Mutated Calreticulin by the Monoclonal Antibody INCA033989 Inhibits Oncogenic Function of MPN

Report on the Academic Paper on the Monoclonal Antibody INCA033989 for Targeting Mutated Calreticulin in Myeloid Tumors Background: Calreticulin Mutation-Driven Myeloproliferative Neoplasms Myeloproliferative neoplasms (MPNs) are hematological malignancies caused by somatic mutations occurring in multipotent hematopoietic stem cells (HSCs). These m...

Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia: A COG-AALL03N1 Report

Review of the Study on Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) Background and Research Question Acute Lymphoblastic Leukemia (ALL) is the most common form of leukemia in children. Current treatment strategies include risk-based induction therapy, response-adapted post-induction therapy,...

Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited

Revisited Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis (FHL) Based on HLH-2004: Updates to Diagnostic Criteria and Development of Multipathway Diagnostic Strategies Introduction Familial hemophagocytic lymphohistiocytosis (FHL) is a severe hyperinflammatory disease characterized by abnormal accumulation of macrophages and l...

Structural Adaptations of von Willebrand Factor, Factor VIII, and Factor IX in Hemostasis

Review Report on the Paper: Structural Adaptations of Von Willebrand Factor, Factor VIII, and Factor IX to Coordinate Complex Functions Background and Research Motivation Coagulation factors are crucial elements of maintaining the dynamic balance of the hemostatic system. Among them, von Willebrand Factor (VWF) plays a central role in hemostasis, p...

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 Cells: Final Phase 2 Trial Results

Inhibition of JAK2/mTOR Fails to Effectively Prevent Acute Graft-versus-Host Disease (GVHD): Limitations of Targeting Th1/Th17 Cells In recent years, the role of systemic immunosuppressive therapies in preventing acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (alloHCT) has come under scrutiny. Th1 (T...

Whole-Genome Analysis of Plasma Fibrinogen Reveals Population-Differentiated Genetic Regulators with Putative Liver Roles

Whole-Genome Analysis of Plasma Fibrinogen Reveals Population-Differentiated Genetic Regulators with Potential Liver Roles Academic Background Fibrinogen is a crucial coagulation factor and acute-phase reactive protein. Under normal physiological conditions, fibrinogen is abundant in circulation, but during the acute inflammatory response, transcri...

Gene Therapy: Genetic Engineering of Transfusable Platelets with mRNA-Lipid Nanoparticles is Compatible with Blood Banking Practices

Report on the Compatibility of mRNA-Lipid Nanoparticle-Based Gene-Engineered Platelets with Blood Banking Practices Academic Background Platelets play an essential role in hemostasis, inflammation, sepsis, and cancer. However, clinical applications of platelet transfusions are primarily limited to managing thrombocytopenia and bleeding. To broaden ...

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients with AML Treated with Venetoclax and Azacitidine

Genetic Risk Stratification and Outcomes Among Treatment-Naive AML Patients Treated with Venetoclax and Azacitidine Academic Background Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with prognosis closely related to the genetic characteristics of patients. The European LeukemiaNet (ELN) 2017 and 2022 risk stratifica...

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study Academic Background Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) are among the most common malignancies in children. Although the cure rate for newly diagnosed ALL and LL patients is relatively high, 10% to ...

Effect of Oral Nintedanib vs Placebo on Epistaxis in Hereditary Hemorrhagic Telangiectasia: The EPICURE Multicenter Randomized Double-Blind Trial

The Effect of Oral Nintedanib vs Placebo on Epistaxis in Hereditary Hemorrhagic Telangiectasia: The EPICURE Multicenter Randomized Double-Blind Trial Academic Background Hereditary Hemorrhagic Telangiectasia (HHT) is a rare genetic disorder characterized by vascular malformations, particularly capillary dilatations. Epistaxis (nosebleeds) is the mo...